Renadyl™ is the outcome of Dr. Natarajan Ranganathan’s meticulous R&D, clinical trials, a pharmaceutical like development and years of efforts to create and grow probiotic bacteria that has the ability to consume uremic toxins in the human intestinal systems as a result of diffusion of uremic toxins from the blood into the bowel and eventually removed from the body. The product will be especially beneficial to patients afflicted with Chronic Kidney failure (diabetes/hypertension/HIV/TB etc.), complementing the standard treatment protocol that they are already undergoing for their specific health problems.
Renadyl™ is currently being sold directly by Kibow Biotech in USA, Canada and now in India through its web store and cold shipped across the world. Renadyl™ is available in capsule form and uses a unique enteric-coated gel cap technology for viable, active and intact delivery for optimal efficacy.
Speaking at the exclusive media launch, Dr. Natarajan Ranganathan said, “Renadyl™ is the outcome of close to 12 years of extensive research and development. Renadyl™ is an oral proprietary dietary supplement that has been scientifically formulated and clinically tested to help support bloodstream concentrations of nitrogenous waste metabolites in the bowel and also stabilize healthy gut flora. Our probiotics formulation of S.thermophilus (KB19), L.acidophilus (KB27) and B. longum (KB31) targets at metabolizing nitrogenous wastes that diffuse from the bloodstream into the bowel. These naturally occurring beneficial microbes have high affinity to metabolize and thus consume the targeted nitrogenous waste products. This is Uremic Toxin Reduction Technology (Enteric Dialysis®) extremely helpful for patients with chronic kidney failure. The company has performed three distinctly different human clinical trials to demonstrate the product for a pharmaceutical-like product validation.”
Explaining The Renadyl™ Technology, he said, “The mechanism takes place in the large intestines. As the kidney’s function slows down, nitrogenous wastes build up in the blood and diffuse into the intestinal fluid by natural physiological process. The nitrogenous wastes diffuse into the colon via an extensive network of blood vessels. The Probiotic microbes enter the large intestine into the ileo-caecal region. Then, once in the colon, the microbes target and metabolize the uremic nitrogenous wastes as nutrients for its growth. The microbes begin to multiply, and this in turn allows for even greater diffusion of nitrogenous wastes from the circulating blood stream into the bowel. Eventually the “nitrogenous waste/microbe” metabolites are eliminated from the body as solid waste/fecal matter.”
Further he said, “Renadyl™ cannot replace dialysis, it is not a drug, medicine or device. It helps to maintain healthy kidney function. Clinical studies have shown that our 3 strains of probiotics have higher affinity for metabolize not only urea and creatinine but scores of other uremic toxins present in a much smaller concentration (micro or nano molar) but much more toxic uremic compounds. These 3 strains are specially grown, selected and will metabolize several nitrogenous waste in the body. They are also enteric coated which renders them unaffected by stomach acids, thus improving efficiency. Moreover these are natural microbes that demonstrate a strong affinity for many of the nitrogenous wastes which accumulate in the blood in the event of kidney failure: urea, uric acid, creatinine, indoles and phenols, nitrosamines and their precursors.”
Probiotics may be taken during antibiotic treatments as well. However, the Probiotic supplements should be taken 2 to 3 hours after the antibiotics treatment. In the case of Renadyl™ Probiotic use should not interfere with the effectiveness of antibiotics if used occasionally.
Speaking on the company’s future plans, Dr. Ranganathan said, “The Company is actively conducting R&D to address other health conditions with pre / probiotic products. We are also seeking direct investments / collaborations to rapidly expand our direct consumer marketing and sales in the USA, India and other overseas markets.”
For more information on Kibow Biotech visit: www.Kibowbiotech.com
About Kibow Biotech:
Founded in 1997, Kibow Biotech is a privately held biotechnology company based in suburban Philadelphia specializing in the development and commercialization of scientifically-formulated and clinically-tested probiotic dietary supplements. Kibow specializes in probiotic supplements for maintaining kidney health and boosting the immunity of the geriatric population by restoring their intestinal microflora. Established to help fight these rapidly growing health risks, Kibow provides the highest quality non-drug dietary supplements at affordable prices.
The company’s mission is to address the improvement of kidney and immune health by utilizing its proprietary probiotics with extensive scientific and clinical drug-like validation. Kibow’s vision is to advance the welfare of people globally by providing superior probiotic supplements and formulations that are effective, safe, economical, and convenient and importantly based on proven science.
Kibow’s products include; Azodyl® for Animals, Renadyl™ for Humans and Kibow Flora® a general immune and wellness probiotic dietary supplement.
